Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 632 participants.
Also called NCT02942576
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 632 participants
- Registry
-
NCT02942576 -
2016-003069-25
-
- Other papers using this trial's data
- Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Belgium, Canada, Czechia, Germany, Hungary, Italy, Poland, South Korea, Spain, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02942576. Randomized; no masking; primary purpose treatment. Start 2017-03-21 (actual); primary completion 2018-09-24 (actual). Results posted on 2019-09-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation
- Acronym
- ELIMINATE-AF
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Edoxaban
- Intervention (Drug)
- VKA-Based Regimen
- Intervention (Drug)
- VKA-Based Regimen
- Intervention (Drug)
- VKA-Based Regimen
- Intervention (Drug)
- VKA-Based Regimen
- Lead sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Record details
- Record id
cardio:ct-nct02942576- Content hash
4bac8724c1cdd4ca2b0403cf880529ef641c934347b700e13a503e18e188dbf2